The aim is to establish the rates of radiation-induced lung disease outcomes, quality of life, and progression-free survival in lung cancer patients treated with Functional avoidance radiotherapy (Arm 1) and Standard radiotherapy (Arm 2)
Functional lung Avoidance SPECT-guided (ASPECT) radiation therapy of lung cancer
Lead Researchers:
Summary:
The aim is to establish the rates of radiation-induced lung disease outcomes, quality of life, and progression-free survival in lung cancer patients treated with Functional avoidance radiotherapy (Arm 1) and Standard radiotherapy (Arm 2)
Clinical trial design:
Randomised double-blinded prospective phase II clinical study with 2:1 randomisation – first arm will receive SPECT functional avoidance while the other receives standard treatment.
More information:
The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198
Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.
Copyright © 2024 TOGA – Thoracic Oncology Group Australasia. No part of this site may be reproduced without our written permission.